Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

- PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population - Trial demonstrated 82% clinical efficacy against Delta variant - Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied - Vaccine was well-tolerated with no safety signals identified - Novavax plans to supplement global regulatory filings with pediatric data in Q1 2022 - Company to host investor conference call today from 4:30 - 5:00 pm ET GAITHERSBURG, Md., Feb. 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness endpoint in the pediatric expansion of its PREVENT-19 pivotal Phase 3 trial and demonstrated 80% efficacy overall at a time when the Delta variant was the predominant circulating strain in the U.S. The study enrolled 2,247 adolescents aged 12 through 17-years across 73 sites in the U.S. to evaluate safety, effectiveness (immunogenicity), and efficacy, with an emphasis on ensuring well balanced racial and ethnic representation among participants.

Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

NVAX stock dropped too sharply on a negative Reuters article about Novavax, creating a great buying opportunity for investors. The post Novavax Stock Is a Buy After This Overdone Sell-Off appeared first on InvestorPlace.

Novavax Stock Is a Buy After This Overdone Sell-Off

Moderna

Shares of vaccine makers rebound Wednesday after Pfizer's 2022 sales guidance fell short of Wall Street's bullish expectations.

Moderna and Novavax Stock Rebound After Slumping on Pfizer's Outlook

They've both been crashing in recent months, but which stock is more likely to recover?

Better Buy: Moderna vs. Novavax

Moderna and Novavax Shares Rebound After Slumping on Pfizer's Outlook

The stock price of Novavax, Inc. (NASDAQ: NVAX) fell by 11.97% in the most recent trading session. This is why it happened.

Novavax (NVAX) Stock: Why The Price Fell

Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch.

Take a Leap Into Novavax Stock After Vaccine Sales Start

Novavax hasn't delivered on an important 2021 promise. The future of NVAX stock looks grim as the vaccine race winds to a tentative close.

NVAX Stock Alert: Why Is Novavax Plunging Today?

Novavax Inc. NVAX shares are trading lower Tuesday after the company acknowledged to Reuters that it has completed delivery of only about 10 million doses of its COVID-19 vaccine. This number comes in much lower than the 2 billion doses that were expected to be delivered around the world.

Why Is Novavax Stock Dipping Tuesday?

Shares of Novavax Inc. NVAX, -12.29% tumbled 12.2% in trading on Tuesday after a Reuters report said there are delays shipping the company's COVID-19 vaccines to Europe and the Philippines in the first quarter of the year. Novavax's vaccine has been authorized in several countries, including the U.K. and New Zealand.

Novavax's stock falls after Reuters report saying COVID-19 vaccine shipments are delayed in some regions

Novavax, Inc. NVAX shares are tumbling Tuesday on a negative headline concerning the Maryland-based biopharma's COVID-19 vaccine. What Happened: Novavax delivered around 10 million vaccine doses thus far as against the target of 2 billion doses for 2022, Reuters reported.

Novavax Tumbles On Reports Of Underdelivering COVID-19 Vaccine Commitments

Novavax, Inc (NASDAQ:NVAX) is plummeting this morning, down 14% to trade at $81.56 at last check, on news that the company has only delivered 10 million doses of its Covid-19 vaccine, after promising to send 2 billion around the world this year.

Novavax Stock Sinks as Vaccine Deliveries Fall Short

Pfizer

The drugmaker expects 2022 revenue of $98 billion to $102 billion, which fell below analyst expectations of $104 billion.

Pfizer drops after issuing weaker 2022 outlook, dragging COVID-19 vaccine makers Moderna and Novavax down with it

GrowGeneration Corp

Pubmatic

Market crashes and corrections are the perfect time for investors to pounce on these deals.

5 Growth Stocks Down 58% to 88% That Are Screaming Buys as the Market Corrects Lower

News that Australia has received its first shipment of Novavax's Covid-19 vaccine has NVAX stock taking off nearly 9% in today's trading. The post NVAX Stock Alert: The Covid-19 Vaccine News Sending Novavax Higher Today appeared first on InvestorPlace.

NVAX Stock Alert: The Covid-19 Vaccine News Sending Novavax Higher Today

Shopify

When the stock market crashes and your favorite stocks are getting killed, it's a good idea to add to your long-term winners.

Buy Your Winners: For Me That's Shopify, Novavax, and Sea

BioNTech SE

Johnson & Johnson

Some of last year's superstars have lost more than 30% since December.

Is it Too Late to Buy Vaccine Stocks?

Redfin

Trulieve Cannabis Corp.

Upstart Holdings

The recent sell-off has created a prime opportunity for investors to pounce on great companies.

5 Discounted Growth Stocks That Can Make You Wildly Rich by Retirement

Despite massive delays, Novavax is expected to obtain the US FDA's Emergency Use Authorization for its COVID-19 vaccine, NVX-CoV2373, in the coming weeks. Given that Israel just ordered 5M of NVX-CoV2373, it could be a strong indication that the mRNA vaccines are less effective against the globally dominant Omicron variant.

Novavax: Finally Leaving No Man's Land

Novavax, Inc. (NASDAQ:NVAX) has had a tough year with losses of approximately 68%. It has already declined about 37% year-to-date, as well.

2022 Could be a Success or a Lost Opportunity for Novavax

Abbott Labs

Fulgent Genetics

6 Stocks That Could Soar If New Coronavirus Variants Emerge

GAITHERSBURG, Md., Feb. 3, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted provisional approval of NVX-CoV2373, Novavax' COVID-19 vaccine (adjuvanted), for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older.

New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine

Novavax's vaccine revenues haven't soared yet. But if the FDA approves the shot, the odds could change for NVAX stock.

Novavax Can Still Succeed, But It's Facing High Risks

Shares of Novavax Inc. NVAX, -6.03% gained 0.9% in premarket trading on Thursday after the company said its COVID-19 vaccine received conditional authorization in the U.K. The protein-based vaccine, which is called Nuvaxovid, requires two shots spaced 21 days apart and can be used in adults. The U.K. has already ordered up to 60 million doses of Novavax's vaccine.

U.K. authorizes Novavax's COVID-19 shot

Covid-19 vaccine developer Novavax's stock indicated on Monday that it had finally officially filed for authorization of its experimental Covid-19 shot in the U.S. after several months of delays. Novavax stock rallied by almost 15% over the last two trading days following the news.

News for Novavax Stock (NVAX)